MannKind Corporation, of Afrezza fame, and United Therapeutics have signed an exclusive licensing and collaboration agreement for dry powder pulmonary hypertension products.
Despite requiring more API, the price of inhaled insulin Afrezza has dropped below that of injected rapid-acting rivals says MannKind's CEO, reporting a resilient Q3.
MannKind has spoken about Receptor Life Science, a newly-formed company which last month licensed the Technosphere inhaled delivery platform from the struggling firm.
Despite Sanofi’s “conflicted” management and subsequent abandonment of Afrezza, the market opportunity for inhaled insulin is still huge, according to Dance Biopharm's CEO.
Sanofi has abandoned Afrezza less than a year after its launch, but the future of the inhaled insulin product is secure according to developer MannKind.
MannKind says it is confident sales of its inhaled insulin product Afrezza - commercialised by Sanofi - will pick up after disappointing growth since launch.
MannKind has cut more jobs in efforts to streamline operations, leaving the inhalable insulin manufacturer around a third smaller than this time last year.
MannKind’s development of new drugs with the delivery technology used in its inhalable insulin drug Afrezza will progress without founder Alfred Mann at the helm.
Two billion cartridges of inhaled insulin drug Afrezza will be manufactured annually by Mannkind, the firm says as it awaits final approval next month.